OCGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Ocugen's EBITDA per Share for the three months ended in Mar. 2024 was $-0.05.
During the past 3 years, the average EBITDA Per Share Growth Rate was -12.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 55.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 58.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ocugen was 85.50% per year. The lowest was -26.20% per year. And the median was 32.80% per year.
For the Biotechnology subindustry, Ocugen's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ocugen's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Ocugen's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Ocugen (NAS:OCGN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of Ocugen's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Junge Zhang | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Quan Anh Vu | officer: CFO/CBO | 22616 ERWIN STREET, WOODLAND HILLS CA 91367 |
Shankar Musunuri | director, officer: Chief Executive Officer | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Arun Upadhyay | officer: Chief Scientific Officer | C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
Ramesh Kumar | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Kirsten Castillo | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Uday Kompella | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Prabhavathi Fernandes | director | 114 MILTON AVENUE, CHAPEL HILL NC 27514 |
Marna C Whittington | director | 2959 BARLEY MILL ROAD, YORKLYN DE 19736 |
Jessica Crespo | officer: CAO/SVP, Finance | C/O OCUGEN, INC., 263 GREAT VALLEY PARKWAY, MALVERN PA 19355 |
Sanjay Subramanian | officer: Chief Financial Officer | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Manish Potti | director | C/O OCUGEN, INC., 5 GREAT VALLEY PARKWAY, SUITE 150, MALVERN PA 19355 |
Vijay Tammara | officer: Vice President | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Suha Taspolatoglu | director | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
Kelly Beck | officer: Vice President | 5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355 |
From GuruFocus
By sperokesalga sperokesalga • 04-26-2023
By sperokesalga sperokesalga • 03-27-2023
By sperokesalga sperokesalga • 05-24-2023
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 03-31-2023
By sperokesalga sperokesalga • 02-17-2023
By Marketwired • 09-28-2023
By GuruFocus Research • 11-09-2023
By sperokesalga sperokesalga • 04-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.